ArticleBiomaterials2014
Cerium oxide nanoparticles attenuate monocrotaline induced right ventricular hypertrophy following pulmonary arterial hypertension.
Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 75 citations in OpenAlex.
- Potential application and prospects of ROS-sensitive biomaterials in cancer therapy: a immune microenvironment triggered nanomaterial.Discover oncology · 2025Review
- A Cardiac-Targeting and Anchoring Bimetallic Cluster Nanozyme Alleviates Chemotherapy-Induced Cardiac Ferroptosis and PANoptosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Au-modified ceria nanozyme prevents and treats hypoxia-induced pulmonary hypertension with greatly improved enzymatic activity and safety.Journal of nanobiotechnology · 2024Article
- Ceria nanoparticles: biomedical applications and toxicity.Journal of Zhejiang University. Science. B · 2024Review
- Hyperoside Prevents Aβ42-Induced Neurotoxicity in PC12 Cells and Caenorhabditis elegans.Molecular neurobiology · 2023Article
- Pegylated nanoceria: A versatile nanomaterial for noninvasive treatment of retinal diseases.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Review
- Article
- Protective effect of cerium oxide on testicular function and oxidative stress after torsion/detorsion in adult male rats.Experimental and therapeutic medicine · 2023Article
- Recent Advances in ROS-Scavenging Metallic Nanozymes for Anti-Inflammatory Diseases: A Review.Chonnam medical journal · 2023Review
- Reactive-oxygen-species-scavenging nanomaterials for resolving inflammation.Materials today. Bio · 2021Review
- Global Proteomics Deciphered Novel-Function of Osthole Against Pulmonary Arterial Hypertension.Scientific reports · 2018Article
- Analytical High-resolution Electron Microscopy Reveals Organ-specific Nanoceria Bioprocessing.Toxicologic pathology · 2018Article
- Shape-Specific Nanoceria Mitigate Oxidative Stress-Induced Calcification in Primary Human Valvular Interstitial Cell Culture.Cellular and molecular bioengineering · 2017Article
- Treatment strategies for the right heart in pulmonary hypertension.Cardiovascular research · 2017Review
- Bio-Adaption between Magnesium Alloy Stent and the Blood Vessel: A Review.Journal of materials science & technology · 2016Article
- Hydroxysafflor yellow A improves established monocrotaline-induced pulmonary arterial hypertension in rats.The Journal of international medical research · 2016Article
- Cerium oxide nanoparticles attenuate acute kidney injury induced by intra-abdominal infection in Sprague-Dawley rats.Journal of nanobiotechnology · 2015Article
- Cerium oxide nanoparticle treatment ameliorates peritonitis-induced diaphragm dysfunction.International journal of nanomedicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
Cerium oxide (CeO2) nanoparticles have been posited to exhibit potent anti-oxidant activity which may allow for the use of these materials in biomedical applications. Herein, we investigate whether CeO2 nanoparticle administration can diminish right ventricular (RV) hypertrophy following four weeks of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH). Male Sprague Dawley rats were randomly divided into three groups: control, MCT only (60 mg/kg), or MCT + CeO2 nanoparticle treatment (60 mg/kg; 0.1 mg/kg). Compared to the control group, the RV weight to body weight ratio was 45% and 22% higher in the MCT and MCT + CeO2 groups, respectively (p < 0.05). Doppler echocardiography demonstrated that CeO2 nanoparticle treatment attenuated monocrotaline-induced changes in pulmonary flow and RV wall thickness. Paralleling these changes in cardiac function, CeO2 nanoparticle treatment also diminished MCT-induced increases in right ventricular (RV) cardiomyocyte cross sectional area, β-myosin heavy chain, fibronectin expression, protein nitrosylation, protein carbonylation and cardiac superoxide levels. These changes with treatment were accompanied by a decrease in the ratio of Bax/Bcl2, diminished caspase-3 activation and reduction in serum inflammatory markers. Taken together, these data suggest that CeO2 nanoparticle administration may attenuate the hypertrophic response of the heart following PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.